Page last updated: 2024-12-11

p-coumaric acid glucoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

p-coumaric acid glucoside: from flaxseed; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-O-beta-D-glucosyl-trans-4-coumaric acid : A 4-O-beta-D-glucosyl-4-coumaric acid in which the double bond has trans-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9840292
CHEMBL ID3978496
CHEBI ID17335
CHEBI ID83032
SCHEMBL ID8430469
MeSH IDM0513768

Synonyms (43)

Synonym
4-o-beta-d-glucosyl-4-coumaric acid
CHEBI:17335
4-o-[4-(2-carboxyvinyl)phenyl]-beta-d-glucopyranose
ACON1_000738
MEGXP0_000649
C04415 ,
NCGC00169406-01
2-propenoic acid, 3-(4-(beta-d-glucopyranosyloxy)phenyl)-
coumaric acid 4-o-glucoside
3-(4-(beta-d-glucopyranosyloxy)phenyl)-2-propenoic acid
7abg62y8ug ,
14364-05-7
unii-7abg62y8ug
(2e)-3-[4-(beta-d-glucopyranosyloxy)phenyl]prop-2-enoic acid
(2e)-3-[4-(beta-d-glucopyranosyloxy)phenyl]acrylic acid
4-o-beta-d-glucosyl-4-hydroxycinnamic acid
CHEBI:83032
trans-beta-d-glucosyl-4-hydroxycinnamic acid
4-o-beta-d-glucosyl-trans-4-coumaric acid
SCHEMBL8430469
CHEMBL3978496
e-4-o-beta-d-glucopyranosyl-p-coumaric acid
coumaric acid o-glucoside
NCGC00169406-02
(e)-3-[4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoic acid
Q7116889
DTXSID101030453
glucosido-p-coumaric acid
4-o-.beta.-d-glucopyranosyl-p-coumaric acid
p-coumaric acid glucoside
glucopyranoside, p-(2-carboxyvinyl)phenyl, .beta.-d-
p-(glucosyloxy)cinnamic acid
4-(.beta.-d-glucopyranosyloxy)cinnamic acid
p-coumaric acid 4-o-.beta.-d-glucopyranoside
4-o-.beta.-d-glucopyranosyl cinnamate
2-propenoic acid, 3-(4-(.beta.-d-glucopyranosyloxy)phenyl)-
3-(4-(.beta.-d-glucopyranosyloxy)phenyl)-2-propenoic acid
cinnamic acid, p-(.beta.-d-glucopyranosyloxy)-
p-coumaric acid .beta.-glucoside
(e)-3-(4-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)phenyl)acrylic acid
4-o-d-glucopyranosyl-p-coumaric acid
AKOS040736222
117405-49-9

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
4-O-beta-D-glucosyl-4-coumaric acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1316661Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1316658Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1316659Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1316660Cytotoxicity against LPS-activated human BV2 cells assessed as cell viability at 30 uM after 24 hrs by MTT assay (Rvb = 98.03 to 98.84%)2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
AID1316657Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction2016Bioorganic & medicinal chemistry letters, 10-15, Volume: 26, Issue:20
Bioactive phenols as potential neuroinflammation inhibitors from the leaves of Xanthoceras sorbifolia Bunge.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's2 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.72 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]